Cite
Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
MLA
Tu, Chien-Lung, et al. “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?” BioDrugs, vol. 33, no. 4, Aug. 2019, pp. 437–46. EBSCOhost, https://doi.org/10.1007/s40259-019-00357-2.
APA
Tu, C.-L., Wang, Y.-L., Hu, T.-M., & Hsu, L.-F. (2019). Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development? BioDrugs, 33(4), 437–446. https://doi.org/10.1007/s40259-019-00357-2
Chicago
Tu, Chien-Lung, Yi-Lin Wang, Teh-Min Hu, and Li-Feng Hsu. 2019. “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?” BioDrugs 33 (4): 437–46. doi:10.1007/s40259-019-00357-2.